CClinicalTrials.gg
CompletedNCT05704686Updated Jan 30, 2023

Clinical Outcomes of an New EDOF IOL (Isopure®)

An observational study in Lens Opacities, Cataract and Pseudophakia, sponsored by Kristof Vandekerckhove, MD, MBA. Completed at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by Kristof Vandekerckhove, MD, MBA · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
62
Ages
50 Years and older
Sex
All
01

Study summary

Single-center, retrospective, open-label observational study aiming to evaluate visual outcomes and patient satisfaction after bilateral implantation of Isopure® EDOF-IOL with a mono-minovision target.

Read the detailed description

This single-center retrospective study investigates visual outcomes and patient satisfaction in subjects bilaterally implanted with Enhanced-Depth of Focus (EDOF) Isopure® IOL during routine bilateral cataract surgery.

The study is carried out in an ophthalmic clinic in Switzerland. In this study, routine surgical techniques and postoperative follow-up will be applied as for all other (non-study) cataract patients in the clinic. Therefore, all study patients will be operated in immediate consecutive bilateral mode (routine in clinic). Patients participating in this study will be recruited and enrolled postoperatively. They undergo routine postoperative follow-up examinations, and data are collected at the third scheduled examination (4 to 6 weeks after surgery) and at a telephone call 4 to 6 months after surgery.

Isopure 1.2.3 is a CE certified intraocular lens readily available on the market in Switzerland.

The primary outcome consists in demonstrating a preserved distance visual acuity while improving binocular spectacle-free intermediate vision and, to a lesser extent, near vision. Binocular defocus curves are measured for each participant to simulate visual acuity at different distances. Patient satisfaction with treatment and subjective ratings of visual phenomena will be assessed using a modified PRISQ questionnaire and a modified NEI quality of vision questionnaire (RQL-42) at the third postoperative visit and three months after surgery.

At Vista Alpina Eye Clinic, mini-monovision is routinely used to further improve binocular intermediate and near vision while preserving the quality of distance vision in patients implanted bilaterally with EDOF Isopure® IOLs. Analysis of the retrospective data should help support this surgical strategy.

Patients with astigmatism up to 1.5 D benefit intraoperatively from Opposite Clear Corneal Incisions (OCCI) to reduce astigmatism. Analysis of our retrospective data will allow comparison of their visual performance with that of patients without astigmatism who did not require an additional OCCI procedure.

02

Conditions studied

  • Lens Opacities
  • Cataract
  • Pseudophakia
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive patients undergoing routine cataract surgery and having opted for the implantation of an EDOF intraocular lens, in a primary ophthalmic clinic in Switzerland.

Inclusion criteria

  • Male or female patients aged 50 years or older undergoing a routine cataract surgery and benefiting from bilateral IOL implantation with Isopure 1.2.3 IOL;
  • Patient's willingness to participate in the study;
  • Capacity to understand and sign an informed consent form and comply with examination procedures;
  • Cataractous eyes with no vision-impacting comorbidity (estimated visual potential post-surgery 0.2 logMAR or better);
  • Regular total corneal astigmatism ≤1.5 D (measured by topography method)

Exclusion criteria

Exclusion Criteria:

  • Cooperation difficulties (distance from home, general health conditions, cognitive impairment);
  • Subjects with diagnosed extra- or intraocular vision-affecting comorbidities (macular degeneration, glaucoma or other retinal or optic nerve disorders, previous ocular surgeries, amblyopia);
  • Patients who previously benefitted from refractive surgery (PRK/LASIK) were included if no refractive surgery-related complications were noted (i.e: ectasia, corneal haze, dry eye);
  • History or presence of macular edema;
  • Perioperative complications;
  • Congenital, uveitic, traumatic or surgically-complicated cataract
  • Regular total corneal astigmatism >1.5 dioptres (measured by topography method)
  • Irregular cornea, including keratotomy
04

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
62 participants (actual)
Patient registry
No

Interventions

  • DeviceIsopure 1.2.3 intraocular EDOF lens implantation

    Bilateral Isopure 1.2.3 intraocular EDOF IOL implantation during a routine cataract surgery.

05

What researchers measure

Primary outcomes

  1. UDVA(m)

    Monocular Uncorrected Distance Visual Acuity

    Time frame: 4-6 weeks postoperatively

  2. CDVA(m)

    Monocular Corrected Distance Visual Acuity

    Time frame: 4-6 weeks postoperatively

  3. UDVA(b)

    Binocular Uncorrected Distance Visual Acuity

    Time frame: 4-6 weeks postoperatively

  4. UIVA

    Binocular Uncorrected Intermediate Visual Acuity (80 cm)

    Time frame: 4-6 weeks postoperatively

  5. UNVA

    Binocular Uncorrected Near Visual Acuity (40 cm)

    Time frame: 4-6 weeks postoperatively

  6. Defocus curve

    Binocular distance-corrected defocus curve analysis simulating visual acuities at different distances.

    Time frame: 4-6 weeks postoperatively

Secondary outcomes

  1. Patient satisfaction with the visual outcome

    (modified) PRISQ questionnaire

    Time frame: 4-6 weeks postoperatively and 4-6 months postoperatively

  2. Subjective rating of visual phenomena

    (modified) NEI quality of vision questionnaire (RQL-42, questions 17 and 38)

    Time frame: 4-6 weeks postoperatively and 4-6 months postoperatively

Other outcomes

  1. Impact of OCCI on residual refractive cylinder

    Residual refractive cylinder in eyes undergoing OCCI (eyes with preoperative topographic total corneal astigmatism 0.6 - 1.5 diopters), compared to eyes not having undergone OCCI (preoperative topographic cylinder 0 - 0.5 diopters).

    Time frame: 4-6 weeks postoperatively

  2. Impact of OCCI on uncorrected binocular visual acuity

    Comparison of binocular UDVA between three subgroups. Subgroup 1: both eyes having undergone OCCI. Subgroup 2: one eyes having undergone OCCI. Subgroup 3: none of the eyes having undergone OCCI.

    Time frame: 4-6 weeks postoperatively

  3. Impact of OCCI on uncorrected monocular visual acuity

    Comparison of monocular UDVA between eyes having undergone OCCI and eyes not having undergone OCCI (eyes with emmetropic objective only)

    Time frame: 4-6 weeks postoperatively

  4. Accuracy of different IOL-formulas

    Comparing various IOL-formulas used to calculate the appropriate IOL power during preoperative assessment. The objective is to determine which IOL formulas are most accurate, overall, and (subgroups) in function of the anatomy of the eye (short vs long eyes, shallow versus deep anterior chamber)

    Time frame: 4-6 weeks postoperatively

06

Study locations

1 site
  • Vista Alpina Eye Clinic
    Visp, 3930, Switzerland
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05704686
Lead sponsor
Kristof Vandekerckhove, MD, MBA
Responsible party
Kristof Vandekerckhove, MD, MBA (Medical Director and Founder, Vista Alpina Eye Clinic, Vista Alpina Eye Clinic) — Sponsor-investigator
First posted
Jan 30, 2023
Start date
Apr 26, 2021
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Last update
Jan 30, 2023

Study contacts

Kristof Vandekerckhove, MD
principal investigator · Vista Alpina Eye Clinic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion